Ribavirin-Free Regimen With Sofosbuvir and Velpatasvir Is Associated With High Efficacy and Improvement of Patient-Reported Outcomes in Patients With Genotypes 2 and 3 Chronic Hepatitis C: Results From Astral-2 and -3 Clinical Trials | Zendy

Zobair M. Younossi | Zendy; Maria Stepanova | Zendy; Mark Sulkowski | Zendy; Graham R. Foster | Zendy; Nancy Reau | Zendy; Alessandra Mangia | Zendy; Keyur Patel | Zendy; Norbert Bräu | Zendy; Stuart K. Roberts | Zendy; Nezam H. Afdhal | Zendy; Fatema Nader | Zendy; Linda Henry | Zendy; Sharon Hunt | Zendy

Open Access

Ribavirin-Free Regimen With Sofosbuvir and Velpatasvir Is Associated With High Efficacy and Improvement of Patient-Reported Outcomes in Patients With Genotypes 2 and 3 Chronic Hepatitis C: Results From Astral-2 and -3 Clinical Trials

Author(s) -

Zobair M. Younossi,

Maria Stepanova,

Mark Sulkowski,

Graham R. Foster,

Nancy Reau,

Alessandra Mangia,

Keyur Patel,

Norbert Bräu,

Stuart K. Roberts,

Nezam H. Afdhal,

Fatema Nader,

Linda Henry,

Sharon Hunt

Publication year - 2016

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1093/cid/ciw496

Subject(s) - medicine , sofosbuvir , ribavirin , regimen , hepatitis c , adverse effect , hepatitis c virus , gastroenterology , surgery , immunology , virus

Until recently, the approved treatment regimens for patients with hepatitis C virus (HCV) genotypes (GTs) 2 and 3 contain sofosbuvir (SOF) and ribavirin (RBV) for 12 or 24 weeks. The impact of RBV-free pan-genotypic regimen with SOF and velpatasvir (SOF/VEL) on patient-reported outcomes (PROs) of patients with genotype 2 and 3 has not been described.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research